The growth that Prestige bought

The annual Barclays consumer conference is where packaged-goods firms queue to parade their formulas for steady, profitable growth. Prestige Consumer Healthcare, which owns Monistat, Clear Eyes, Dramamine and a shelf of other over-the-counter stalwarts, brings a number worth a second look: management now guides to $1.29–1.32 billion of revenue for fiscal 2027, up from $1.09 billion the year before. That is a jump of nearly a fifth, delivered in a single year, and it is the kind of figure that earns a standing invitation to the stage.

The trouble is that the number flatters. Strip out the brands the company just bought, and organic growth is still guided at a humble 1–3%. Prestige has never really been a growth company in the ordinary sense. It is a collector of brands that bigger drugmakers have tired of, run on an asset-light basis at fat margins and milked for free cash that gets returned through buybacks and debt pay-down. Over the five fiscal years to March 2025 its organic compounding ran at 2.4% a year. In effect it is a private-equity firm that happens to hold a listing: value is created at the deal table and on the balance sheet, not in the market for nasal strips.

When the machine stumbled

For a while the machine hummed. Fiscal 2025 set records, with adjusted earnings per share of $4.52. Then the model tripped. In fiscal 2026 revenue fell 4.5% on an organic basis and adjusted EPS slipped to $4.38, dragged down mostly by the eye-care business. Clear Eyes ran low on supply because the sterile factory Prestige had bought to make it (Pillar5 Pharma) needed remediation, taking millions in costs and idle capacity. A business whose entire promise is steady cash in, more cash out had suddenly looked less steady.

The remedy was the familiar one, applied at scale. In March 2026 Prestige agreed to pay Foundation Consumer Healthcare $1.045 billion for Breathe Right, Dimetapp, Anbesol and other brands — roughly 11 times the $95 million of EBITDA that portfolio earned in 2025, or 9.5 times once $150 million of expected tax benefits are counted. Breathe Right, the nasal strip, brings a category Prestige did not previously own, roughly 60% of the American nasal-strip market and household penetration of only about 3%. That last figure is the crux of the pitch: a low-penetration, category-leading brand can be framed not as a harvest but as a growth platform with room to run.

What the borrowed growth costs

Buying that growth is expensive. To pay for the deals, Prestige nearly doubled its net debt, to about $2 billion, and levered itself to roughly four times EBITDA at closing, promising to work back below three times by fiscal 2028 on the strength of close to $900 million of free cash over three years. The fiscal 2027 top line the company will crow about at Barclays is therefore financed at an 11-times multiple, with acquisitions supplying the difference between 1–3% organic growth and the double-digit reported jump.

The adjusted earnings on which the whole pitch rests also carry a growing load of deal accounting. In the first quarter of fiscal 2027, reported EPS was $0.61 while the adjusted figure was $0.98; the gap is filled by factory remediation, inventory step-up amortisation and acquisition-related overhead. None of this is sharp practice, and much of it will fade as integration is completed. But it does mean the profits the market prices are being shaped by bookkeeping associated with three purchases closed within months — and by the hope that the new brands, once digested, grow.

At a market value near $2.5 billion — on top of that $2 billion of debt — the shares trade at only about eleven times forward adjusted earnings, having fallen about a tenth in 2026. AInvest's aggregate signal labels the shares a buy, and its composite and fundamental scores are strong. That is a mechanical cross-check, not a verdict: the multiple is only defensible if organic growth at the 2–3% target actually resumes across the enlarged portfolio.

The applause at Barclays will be for the top line. The discipline that will decide the investment case lies elsewhere — in whether free cash, after servicing $2 billion of debt, repays that leverage quickly enough that the next acquisition becomes a matter of choice rather than necessity. If it does not, the machine must keep buying simply to stand still, and the growth on the slide is a cost, not a creation.